Parathyroid hormone-related protein (PTHrP) is an integral mediator of physiologic and pathologic processes and has demonstrated actions in the periodontium. PTHrP functions via AP-1, and specifically through JunB. This study identified JunB-dependent downstream mediators of PTHrP using OCCM cementoblastic transfectants with JunB over-or reduced expression. Overexpressing cells showed an increase in proliferation, while the opposite was seen in siRNA transfected cells. Microarray analysis of over-expressing cells revealed more than 1000 regulated genes. Three genes were investigated in more detail. The PTH⁄PTHrP receptor (PTHR1) and ephrin B1 (EfnB1) were down-regulated, and vascular cell adhesion molecule-1 (VCAM-1) was up-regulated with JunB over-expression. JunB siRNA transfectants had increased PTHR1, but reduced ephrin B1 and unaltered VCAM-1 in vitro. To validate these targets, parental OCCM cells and primary osteoblasts were treated with PTHrP, resulting in reduced PTHR1 and ephrin B1, and increased VCAM-1. Cell transfectants were implanted subcutaneously in vivo, and microarray analysis and RT-PCR performed. Over-expression of JunB downregulated PTHR1 and ephrin B1, and increased VCAM-1. JunB siRNA transfectant implants had increased PTHR1 and ephrin B1, but no altered VCAM-1. These data highlight new gene targets for PTHrP and indicate JunB is a critical mediator of PTHrP actions. Oral Diseases (2008) 14, 713-726 
Introduction
Parathyroid hormone-related protein (PTHrP) is an autocrine, paracrine or intracrine factor during normal development and pathologic conditions (Fiaschi-Taesch and Stewart, 2003) . PTHrP binds to the PTH ⁄ PTHrP receptor (PTHR1) on osteoblasts and cementoblasts to invoke numerous downstream genes in a similar manner as PTH, which binds to the same receptor (Gensure et al, 2005) . Signaling through the PTHR1 is primarily through the PKA pathway, but the PKC and the MAPK pathways also participate in PTH and PTHrP actions in bone (Gensure et al, 2005) .
Members of the AP-1 family of transcription factors have prominent roles in skeletal development and homeostasis (Eferl and Wagner, 2005) . More than 45 genes important in bone have AP-1 sites in their promoter region (Yamashita and McCauley, 2006) , and gene deletion and transgenic models of AP-1 factor over-expression have revealed critical roles for Fos and Jun family members in osteoblastic and osteoclastic cell lineages (Jochum et al, 2001) . PTH and PTHrP treatment of osteoblasts results in a dramatic up-regulation of AP-1 family members (Yamashita and McCauley, 2006) , and previous studies from our laboratory have characterized the AP-1 response in osteoblasts and cementoblasts (Berry et al, 2006) . Cementoblasts are mesenchymal cells located on the tooth root surface which have osteoblast phenotypic characteristics (Saygin et al, 2000) . PTHrP binds to its receptor on cementoblasts and up-regulates all of the Fos family members, but only the JunB protein of the Jun family (Berry et al, 2006) . JunB has been found to function in osteoblasts, osteoclasts, and cementoblasts (Kenner et al, 2004; Berry et al, 2006) ; hence identifying the downstream genes that PTH and PTHrP activate through JunB would be a valuable aid in exploring the effect of these important compounds on mineralized tissues.
Parathyroid hormone and PTHrP support osteoclastogenesis via the up-regulation of RANKL and down-regulation of osteoprotegerin (OPG) (Lee and Lorenzo, 1999) , and PTHrP is critical for the support of osteoclasts in the developing alveolar bone, as mice with compromised PTHrP signaling lack tooth eruption (Philbrick et al, 1998) . Unlike osteoblasts, cementoblasts do not normally support osteoclastogenesis, however PTHrP influences osteoclastogenesis by cementoblasts at least in part through PTHrP's action via JunB. Cementoblasts produce high levels of osteoprotegerin, and JunB activation via PTHrP results in a diminution of OPG and a resulting increase in osteoclastogenesis (Boabaid et al, 2004) . However, neither the diminution of OPG nor an up-regulation of RANKL can explain the entirety of PTHrP actions. The purpose of the current study was to identify novel downstream mediators of PTHrP action via its upregulation of JunB in a mesenchymal cementoblastic cell line in vitro, and validate these findings in an in vivo implant model.
Materials and methods
Cell culture and transfection A subclone of the OsteoTag mouse-derived cementoblast cell line named OCCM.30 (OCCM) was cultured as previously described (D'Errico et al, 2000) . Briefly, cells were maintained in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum and 100 U ml )1 penicillin and 100 lg ml )1 streptomycin (Invitrogen) at 37°C in a humidified atmosphere of 5% CO 2 . Primary calvarial cells were isolated as previously described and cultured under the same conditions (Koh et al, 1999) .
Constructs were developed for over-and underexpression of JunB as previously described (Berry et al, 2006) . For over-expression of JunB, full-length junB was cloned into pEF6⁄V5-His TOPO TA expression vector (Invitrogen). The JunB over-expressing vector or a vector alone control was transfected into OCCM cells using a cationic lipid reagent (Lipofectamine 2000; Invitrogen) and stable transfectants were established then subcloned. Levels of JunB over-expression in transfectants were measured using an AP-1 specific ELISA (Active Motif, Carlsbad, CA, USA), and also by Western hybridization. Subclones were screened on the basis of expression level, and subclones of each line (over-expressing and vector) were selected for further study, hereafter referred to as over-expressing Jun B (OEJB.8) and vector control (OEV) respectively. OEJB.8 exhibited an approximately 7-fold increase in JunB expression as compared with the OCCM parental clone and OEV. For reduced expression of JunB, a custom pool of junB siRNA constructs were made by Dharmacon Research (Lafayette, CO, USA), which was employed in transient transfection experiments using a cationic lipid reagent (Oligofectamine, Invitrogen). The most effective sequence for silencing from the pool was determined to be GGATCCCAA-ATGCGCTCCTGGTCTTCCATTGATATCCGTGG-AAGACCAGGAGCGCATTTTTTTTTCCAAAAG-CTT. This was synthesized by GenScript (Piscataway, NJ, USA) and cloned into siRNA expression vector pRNAT-U6.1⁄Neo for stable transfection. The negative control was a nonsense construct, pRNAU-6.1/Neo/ CTL, also from Genscript, containing sequence GGAT-CCCGTCGCTTACCGATTCAGAATGGTTGATAT-CCGCCATTCTGAATCGGT. The silencing constructs and controls were transfected into OCCM cells using Lipofectamine 2000 (Invitrogen), and stable transfectants were established and subcloned. Levels of JunB under-expression were measured as above, and subclones of each line (under-expressing and nonsense control) were selected for further study, hereafter referred to as Si6.1 and control SiV. Si6.1 exhibited a level of JunB expression approximately half that of the vector control.
For PTHrP treatment experiments, cells were plated at 2 · 10 4 cells cm )2 in 60-mm dishes in DMEM supplemented as described above. On day 4 after plating, medium was switched to DMEM with 5% FBS, and on day 7 cells were treated with vehicle control or 100 nM PTHrP (1-34) (Bachem, King of Prussia, PA, USA) for various time periods, after which cells were harvested for protein or RNA isolation.
Cell enumeration and apoptosis
To determine cell numbers over time, cells were plated at a density of 1.04 · 10 3 cm )2 in 6-well plates. Beginning on day 3 after plating, triplicate wells were trypsinized and counted daily for 7 days using trypan blue exclusion to determine viability.
To evaluate apoptosis, cell transfectants were plated at approximately 2.4 · 10 4 cm )2 in 100 mM dishes and 2 days later harvested after a PBS wash, by scraping in CelLytic MT mammalian tissue lysis extraction reagent (Sigma-Aldrich, St Louis, MO, USA) with 1% Protease Inhibitor Cocktail (Sigma). Lysates were incubated on ice for 30 min with vortexing every 10 min, then centrifuged at 22 000 g at 4°C for 20 min. Supernatants were stored at )80°C until analyzed via Western blotting. Cell viability as measured by trypan blue dye exclusion was verified to be similar in parallel cultures of the transfectants. Positive controls included OEV cells treated with the pro-apoptotic agent staurosporine (25 nM) (Sigma) for 6 h.
Western blot analysis was performed after running 30 lg of each sample on 10% acrylamide gels. Filters were blocked for 1 h in 5% non-fat milk in Tris-buffered saline with Tween-20 (TBST), probed overnight with caspase 3 (Becton Dickinson, Franklin Lakes, NJ, USA) and poly(ADP-ribose) polymerase-1 (PARP-1) (Cell Signaling, Danvers, MA, USA) antibodies, then rinsed with TBST and probed with appropriate secondary antibodies (GE Healthcare, Piscataway NJ, USA). After extensive rinsing with TBST, filters were incubated with enhanced chemiluminescence reagents (Pierce Biotechnology, Rockford, IL, USA) and exposed to BioMax film. Bands were normalized with actin, and compared using either SCION IMAGE analysis program (Scion Corporation, Frederick, MD, USA) or a Chemidoc visualization⁄quantification system (Bio-Rad Laboratories, Hercules, CA, USA). Relative band densities were evaluated using INSTAT statistical analysis program (GraphPad, San Diego, CA, USA).
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In vivo experiments All animals were maintained in accordance with NIH and institutional animal care guidelines, and experimental protocols were approved by the Institutional Animal Care and Use Committee of the University of Michigan. Transfected cell lines were implanted subcutaneously in a similar manner as previously described for bone marrow stromal cells (Pettway et al, 2005) . Briefly, 1 · 10 6 cells were placed in a gelfoam carrier sponge and implanted over the backs of athymic nude mice (Harlan, Indianapolis, IN, USA) under anesthesia. Four weeks later, mice were sacrificed and implants were removed and either prepared for histology or immediately frozen at )70°C for further processing and evaluation of RNA.
Protein isolation and analysis
For determination of JunB levels, nuclear extracts were prepared and analyzed using both the TransAM AP-1 Family Transcription Factor Assay System (Active Motif) and Western hybridization (Novex gels; Invitrogen). Briefly, cells were collected in cold PBS in the presence of phosphatase inhibitors and resuspended in a hypotonic buffer. Detergent was added to cause leakage of cytoplasmic proteins into the supernatant, which was removed. Nuclei were lysed and nuclear proteins were solubilized in a lysis buffer containing protease inhibitors. Samples were stored at )70°C until the assays were performed. Total protein levels were equalized as measured using a Bradford-based assay (Bio-Rad), and specific ELISA and Western hybridization were performed to detect JunB. ELISAs were performed a minimum of three times, and protein expression data were analyzed using INSTAT statistical software (GraphPad). Western blots were performed a minimum of three times, and actin was measured in each sample as a loading control (both antibodies Santa Cruz Biotechnology, Santa Cruz, CA, USA). Western films were scanned, and relative protein expression was quantified using either SCION IMAGE analysis program (Scion Corporation) or a Chemidoc visualization⁄quantification system (Bio-Rad). Relative band densities were evaluated using INSTAT.
RNA isolation and analysis RNA from both cells and implants was isolated using Trizol (Invitrogen) and phase-lock gel (Eppendorf, Westbury, NY, USA). In the case of cells, Trizol was added directly to the plate, cells were scraped, and solution was transferred to a tube containing phase-lock gel for further processing. In the case of implants, the tissue, flash frozen in liquid nitrogen immediately after removal from the mouse, was crushed in liquid nitrogen, mixed with Trizol, and this mix of tissue and Trizol was then transferred to a tube containing phase-lock gel. In both cases, samples were centrifuged, precipitated in isopropanol, resuspended in DEPC-treated water, and quantified spectrophotometrically. RNA samples to be examined by microarray or real-time RT-PCR were further purified, including treatment with DNAse using an RNeasy kit (Qiagen, Valencia, CA, USA).
For Northern hybridization, 2-3 lg of RNA was denatured, fractionated by electrophoresis on 1.2% agarose 6% formaldehyde gel, transferred to a nylon membrane (Duralon, Stratagene, La Jolla, CA, USA), and cross-linked by UV radiation. Blots were hybridized with random-primed [a 32 -P] labeled probes (Rediprime; GE Healthcare) and were exposed to Kodak X-Omat or Biomax film with intensifying screens at )70°C for 4-24 h. Probes used included bone sialoprotein (BSP) (Young et al, 1994) , osteocalcin (OCN) (Celeste et al, 1986) , and junB (McCabe et al, 1995) . A cDNA for 18S rRNA was used to probe and normalize blots. Northern blot experiments were repeated a minimum of three times using independent RNA samples, films were scanned, and relative gene expression was quantified using SCION IMAGE analysis program (Scion Corporation) after subtraction of background. Data were analyzed using INSTAT statistical software (GraphPad).
For microarray analysis, total RNA samples were evaluated spectrophotometrically to determine concentration and purity, and RNA integrity was validated by running on an agarose gel. Ten microgram of total RNA was quantitatively amplified and biotin-labeled according to the GeneChip Expression Analysis Technical Manual (Affymetrix, Inc., Santa Clara, CA, USA). Briefly, RNA was converted to double-stranded complementary DNA (cDNA) using SuperScript II RT (Invitrogen), with a T7-(dT) 24 primer (Affymetrix). The cDNA was then used in an in vitro transcription reaction in the presence of biotin-modified ribonucleotides (Enzo, Farmingdale, NY, USA) to produce large amounts of single stranded RNA. Biotin-labeled RNA was fragmented and 10 lg was hybridized to GeneChip array ÔMouse Genome 430A' (Affymetrix) at 45°C for 16-h. Labeled bacterial RNAs of known concentration were spiked in hybridization to generate an internal standard and to allow normalization between chips. Chips were washed and stained with streptavidin R-phycoerythrin (Molecular Probes, Eugene, OR, USA). After scanning the chips, the data were analyzed by using Affymetrix GeneChip related software including GCOS and Data Mining Tool. The microarray experiments were performed three times (in vitro samples twice, in vivo samples once) and selected genes were validated by real-time RT-PCR.
Real-time quantitative RT-PCR utilized the ABI 7500 system (Applied Biosystems, Foster City, CA, USA). For reverse transcription (RT), a 25 ll RT reaction with 0.5 lg total RNA and random hexamers was performed using TaqMan Ò Reverse Transcription Reagents (Applied Biosystems). PCR was performed by using TaqMan Ò Universal PCR Master Mix (Applied Biosystems). Briefly, a 30 ll PCR reaction was prepared with 1 ll cDNA (RT product) and 1.5 ll mixture of TaqMan Gene Expression Assays probe and primers mixture, specified as follows: PTHR1 ABI# Mm00441046_m1 with probe sequence CTGCACA-CAGCAGCCAACATAATGG, NBI Accession# NM_011199.1; VCAM1 ABI# Mm00449197_m1 with probe sequence GGAGGTCTACTCATTCCCTGAA-GAT, NBI Accession no. NM_011693.2; EfnB1 ABI# PTHrP and JunB JE Berry et al Mm00438666_m1 with probe sequence CTGGAGCT-CTCTTAACCCTAAGTTC, NBI Accession # NM_ 010110.2. Thermal conditions were: 50°C 2 min, 95°C 10 min followed by 40 cycles of 95°C 15 s and 60°C 1 min. Expression levels of genes of interest were normalized by comparison to TaqMan Rodent GAPDH Control Assay of each sample. Real-time RT-PCR was repeated a minimum of three times with similar results.
Results
Over-expression of JunB increases, and silencing inhibits, proliferation in cementoblasts The OCCM cementoblastic cells were easily transfected, and numerous subclones of JunB over-expressing and siRNA lines were generated. Cell lines were screened at the RNA and protein levels to validate the expected altered gene expression ( Figure 1 ). Several cell lines were evaluated in the various assays, and selected clones are shown. The OEJB.8 subclone of JunB over-expressing cells displayed an approximately 7-fold increase in mRNA for junB and an approximately 2-fold increase in protein levels compared with OEV, the vector control. The Si6.1 subclone of JunB siRNA cells displayed a 45% decrease in mRNA for junB and a 50% decrease in protein levels compared with its vector control, SiV. As AP-1 family members have been reported to alter cell proliferation, an evaluation of cell numbers over time was performed. Over-expression of JunB resulted in increased cell numbers after 5 days ( Figure 2a ). In contrast, knock down of JunB resulted in lower numbers of cells over time ( Figure 2b ). Western hybridization analysis examining cleavage of PARP-1 and caspase-3 were performed to characterize the difference in cell numbers relative to apoptosis (Figure 2c ). The OEJB.8 transfectants showed a small but detectable band of cleaved PARP, however there was no significant cleavage of PARP-1 or caspase-3 in any of the cell transfectants either over-or under-expressing JunB, suggesting that apoptosis was not a prominent occurrence under the culture conditions. These data indicate that the increase in cell numbers associated with JunB over-expression is not because of reduced apoptosis, but instead because of changes in proliferation.
Genes altered by JunB up-regulation in vitro, PTHR1, VCAM-1 and EfnB1, identified by microarray and validated by real-time RT-PCR AP-1 sites are present in a wide variety of genes, many of which are important in mineralized tissues (Yamashita and McCauley, 2006) . To elucidate genes that are specific targets of JunB action, a microarray analysis was performed on the OCCM transfectants that overexpressed JunB as compared with control transfectants. There were more than 600 genes identified as being upregulated 2-fold or more by JunB and more than 750 genes identified as being down-regulated 2-fold or more by JunB (Table 1 and Supporting information). If genes were detected more than once per chip, the fold change is seen as an average of the values.
Several genes of interest were studied further, and three were evaluated in detail and presented here. The PTHR1 was selected because it was found to be highly down-regulated by JunB over-expression in the microarray (28-fold) and because it is well known to be downregulated by PTH and PTHrP at the RNA level, but very little information exists regarding the operative transcriptional mediators. JunB over-expression nearly abolished expression of the PTHR1 as measured by realtime PCR and a 2.5-fold increase in the PTHR1 was found in the junB siRNA transfectants as compared with the control transfectants (Figure 3a) . Vascular cell adhesion molecule-1 (VCAM-1) was selected because it was found to be up-regulated 3-fold in the microarray data with over-expression of JunB, because it has not yet been reported to be mediated by PTHrP, and because of its reported role in osteoclastogenesis (Michigami et al, 2000) . Validation by RT-PCR revealed an approximately 2.5-fold up-regulation of VCAM-1 by JunB over-expression, however no regulation was found when JunB was silenced (Figure 3b ). Ephrin B1 (EfnB1) was selected because it was down-regulated 5-fold by the over-expression of JunB in OCCM cells in the microarray analysis, because it had not been previously reported to be a PTHrP target and because of its novel role in craniofacial development (Twigg et al, 2004) . Ephrin B1 was dramatically down-regulated by JunB over-expression as confirmed by RT-PCR with levels at 10% of controls (Figure 3c ). However, silencing JunB did not result in an opposite effect, as siRNA for JunB also resulted in down-regulation of Ephrin B1 in vitro as measured by RT-PCR, although to a much lesser extent. (Figure 3d ). When JunB was silenced, PTHrP treatment did not lower the PTHR1 or ephrin B1 levels to the same extent as it did in controls, suggesting that JunB is key for the gene effects. Interestingly, the VCAM levels were similar and elevated with PTHrP regardless of JunB silencing, suggesting JunB may not be the only factor to contribute to the PTHrP mediated increase in VCAM-1 (Figure 3e ).
Silencing of JunB attenuates PTHrP effects in cementoblasts
Increase in junB expression levels precede effects of PTHrP on PTHR1, EfnB1 and VCAM-1 in cementoblasts and osteoblasts To substantiate that JunB regulation resulted in downstream gene alterations that were consistent with a PTHrP effect, parental OCCM cells were treated with PTHrP and gene expression for PTHR1, VCAM-1 and Ephrin B1 was measured by RT-PCR over time. There was significant down-regulation of PTHR1 and ephrin B1 at 4 and 8 h (Figure 4a ). PTHR1 remained significantly down-regulated at 24 h, while ephrin B1 recovered slightly (not shown). VCAM-1 mRNA levels were significantly up-regulated by PTHrP at 4 and 8 h (Figure 4a ), and stayed significantly elevated at 24 h. To compare the PTHrP impact on cementoblasts with osteoblasts, similar experiments that focused on the early time-points where the greatest change was found were performed with primary osteoblastic cells in vitro. Osteoblasts displayed a similar trend with increased expression of (Figure 4c) . Notably, in all studies osteoblasts had higher baseline values of VCAM-1 than cementoblasts, and although they did display a PTHrPmediated increase in VCAM-1, they did not have as dramatic an up-regulation in response to PTHrP. Gene expression for junB in response to PTHrP followed an earlier time course consistent with junB preceding the downstream gene expression. Maximal expression of junB in response to PTHrP in cementoblasts and osteoblasts was 1-2 h (Figure 4b,d ).
Effects of JunB over-expression evaluated in vivo
In vitro model systems are powerful tools to identify gene targets and begin to sort out mechanisms of protein action, but at times do not always replicate the in vivo state because of a plethora of other cells and factors that can modify target gene expression. To validate the in vitro findings in the context of a whole animal, OCCM transfectants were implanted subcutaneously into immunocompromised mice. Cementoblast implants were examined histologically and mRNA was isolated and gene expression analyzed by microarray and realtime PCR. Control implants presented with a welldefined proliferation of cells with round to elongated basophilic nuclei (Figure 5a,c,e) . A prominent accumulation of eosinophilic calcified material consistent with osteoid or cementum was found forming a fine meshwork of trabeculae lined by cells with hyperchromatic angular nuclei. Cells were also contained within lacunar spaces within the calcified material similar to osteocytes or cementocytes. Numerous small vascular channels were observed throughout the control specimens. Implants with cells over-expressing JunB (Figure 5b,d) presented as densely cellular with a brisk mitotic rate, abundant pleomorphism, less vascularity than vector implants and lacked visible mineralization. A palestaining, basophilic acellular material representing residual gelfoam scaffold was found in the JunB overexpressing implants but very little in other implants. The implants with silencing transfectants appeared similar to the vector controls. (Figure 5f ).
The overall size of the implants upon gross examination revealed reductions in the size of implants that contained either the JunB over-expressing or the silenced transfectants (Figure 5g) . To ascertain the impact of JunB on parameters of differentiation relative to cell mineralization, OCN gene expression was determined in implants from transfectants. Silencing of JunB led to increased OCN whereas overexpression of JunB led to a dramatic down-regulation of OCN (Figure 5h ).
Microarray analysis of gene expression influenced by
JunB in vivo examined and validated by real-time RT-PCR Microarray analysis of implants from mice with overexpressing transfectants revealed more than 700 genes up-regulated 2-fold or greater and more than 1250 genes down-regulated (Table 2 and Supporting information). If genes were detected more than once per chip, the fold change is seen as an average of the values. Similar to the in vitro findings, the PTHR1 was nearly abolished by JunB over-expression, whereas silencing resulted in an up-regulation of the PTHR1 as determined by real-time PCR (Figure 6a ). Over-expression of JunB in implants resulted in a dramatic 8-fold increase in VCAM-1 but no alteration was found with silencing of JunB in vivo (Figure 6b ). Ephrin B1 was down-regulated 3-fold in vivo with JunB over-expression and, unlike the results found in vitro, up-regulated significantly with JunB silencing (Figure 6c ).
Comparison of genes regulated in vivo and in vitro A comparison of genes regulated in vitro and in vivo was performed as a means to better understand the JunB gene targets (Table 3 and Supporting information). Of note, genes associated with late stages of mineralization such as BSP, OCN and dentin matrix protein-1 (DMP-1) were down-regulated, and to a greater extent in vivo A selected list of genes altered by JunB over-expression is provided here (see Supporting information for more extensive list). Genes evaluated in detail are indicated in bold. For genes detected more than once in the array, fold change is expressed as an average of all readings.
PTHrP and JunB JE Berry et al than in vitro. Furthermore, the inhibitor of mineralization, matrix gla-protein was up-regulated. This suggests that JunB is associated negatively with mineralization, but could also reflect a later stage of cell differentiation operative in the in vivo model.
Discussion
The present study identified new gene targets of PTHrP that are downstream of JunB in cementoblast cells and characterized these both in vitro and in vivo. PTH and . Ephrin B1 levels were 2.4-fold lower at 4 h and 1.9-fold lower at 8 h (P < 0.05 vs time zero). VCAM-1 levels were 2.9-fold higher at 4 h and 3.1-fold higher at 8 h (P < 0.05 vs time zero). (b) Parental OCCM cells were treated for 0-6 h with 100 nM PTHrP and gene expression measured by northern blot analysis. junB levels were maximal at 1-2 h and decreased thereafter. (c) Primary murine calvarial cells were isolated and cultured to confluence, followed by differentiation with 50 lM ascorbic acid for 7 days. Cells were then treated for 0-4 h with PTHrP (100 nM) and gene expression measured by real-time RT-PCR. PTHR1 levels were 1.4-fold lower at 2 h and 2.8-fold lower at 4 h (P < 0.001 for both) compared with time zero. Ephrin B1 levels were 1.3-fold lower at 2 h (P < 0.05) and 1.4-fold lower at 4 h (P < 0.01) compared with control. VCAM-1 levels were 1.3-fold higher at 4 h (P < 0.01) compared with time zero. (d) Primary calvarial cells were treated for 0-6 h with 100 nM PTHrP and gene expression measured by northern blot analysis. junB levels were maximal at 1-2 h and decreased thereafter. Data for a, c are plots from representative experiments repeated 2-3 times with similar results and expressed as mean ± s.e.m. of triplicate samples. Data for b, d, are representative blots from experiments repeated a minimum of three times with similar results
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regulates it in primary calvarial cells (Yang and Gerstenfeld, 1996; Ogata et al, 2000) . Such apparently contradictory findings have complicated the elucidation of mechanisms of action of PTH and PTHrP in mineralized tissues, but also suggest that the in vivo effects of PTH and PTHrP may be indirect, and hence other cellular targets may be operating in the downstream events.
Regarding a difference in pro-vs anti-proliferative effects of PTHrP: in differentiated osteoblastic cells the effect of PTH or PTHrP is to inhibit proliferation; however, in sparsely seeded cultures in vitro or in an in vivo implant model, PTH and PTHrP clearly lead to pro-proliferative effects (Datta et al, 2005 (Datta et al, , 2007 Pettway et al, 2008) . In the present study, as the over-expressing transfectants have elevated JunB from the initiation of . Implants from JunB silenced cells (Si6.1) were similar in appearance to respective vector controls (SiV). Scale A-F = 100 lm. (g) Implant size (n = 4-7⁄gp) Both over-expression and siRNA for JunB resulted in smaller implants than respective controls. (h) Osteocalcin (OCN) expression in implants (n = 2-4⁄group). OCN was significantly increased in implants with siRNA knock down of JunB and significantly decreased in implants with JunB over-expressing transfectants (P < 0.0001 for each compared with control) PTHrP and JunB JE Berry et al culture, they likely display the pro-proliferative JunB effects that could be attributed to early PTHrP administration. JunB under-expressing cells, on the other hand, show a lower rate of proliferation, which is consistent with the lower proliferation rate seen in osteoblasts obtained from mice lacking JunB (Kenner et al, 2004) . In neither case was apoptosis, as measured by PARP-1 and caspase-3 cleavage, an evident factor in influencing cell number. However, an exhaustive analysis of the proliferative and apoptotic aspects of PTHrP on mesenchymal cells was not performed in this study, as it was the focus of previous reports, as mentioned above, and as the goal for this study was to concentrate on downstream gene events.
One of the goals of the current study was to reveal new gene targets that are operative both in vitro and in vivo as a means to better identify the cellular targets and mechanisms of PTH and PTHrP actions in mineralized tissues. Three gene targets were identified and characterized in further detail. The PTHR1 has previously been identified as a down-regulated gene target of PTH and PTHrP action in bone and cementum and served in part to validate the model system. Ephrin B1 was also down-regulated and was intriguing for its known role in Microarrays were performed using RNA isolated from cementicle implants in athymic mice. Implants were generated using JunB overexpressing cells (OEJB.8) or vector control (OEV). A select list of genes altered by JunB over-expression is provided here (see Supporting information for more extensive list). Genes evaluated in detail are indicated in bold. For genes detected more than once in the array, fold change is expressed as an average of all readings. craniofacial development. VCAM-1 was found to be up-regulated, and this study is the first to identify it as a gene target in response to PTH or PTHrP. The PTHR1 is a seven transmembrane domain receptor that is well characterized as being present in the PTH target organs of bone and kidney. The PTHR1 is the product of a complex gene extending over 22 kb and consisting of 15 exons and is well conserved across species (Kong et al, 1994) . Very little has been reported of its transcriptional controls and promoter elements. PTH and PTHrP have been reported to down-regulate the PTHR1 at the mRNA level but AP-1 regulation of the PTHR1 promoter has not been described. The significance of PTH and PTHrP down-regulating their own receptor is obvious, as it forms an easily regulatable feedback system to prevent over-stimulation of the PTHR1. Constitutive activation of the PTHR1 results in the condition of Jansen's chondrodysplasia (Schipani et al, 1995) . A notable mouse model of constitutive activation of the PTHR1 demonstrates an anabolic phenotype in trabecular bone (Calvi et al, 2001) . That PTHrP and JunB down-regulate the PTHR1 suggest that they may be working to prevent and⁄or balance the PTHR1 mediation of high bone mass and⁄or restrict or limit the progress of tooth eruption that is dependent on PTHrP expression.
Ephrin B1 is a member of a family of ligands for ephrin receptors (Eph) (Davy and Soriano, 2005) . The Eph family is the largest family of protein tyrosine kinase receptors and consists of six ephrin B receptors (EphB) and 10 ephrin A receptors (EphA) (Zhao et al, 2006) . The cell surface ephrin Bs (ephrins B1-B3) are ligands for the EphBs and the ephrin As (ephrin A1-A5) are ligands for the EphAs. Recently there is an evidence that ephrins play critical roles in bone, and specifically in the signaling between osteoblasts and osteoclasts (Zhao et al, 2006) . Interestingly, mutations in ephrin B1 in humans have been found to be responsible for a craniofacial abnormality called craniofrontalnasal syndrome (Twigg et al, 2004) . Humans with this gene mutation typically have hypertelorism, a nasal groove, craniosynostosis and often present with cleft lip and palate (Wieacker and Wieland, 2005) . Mice with targeted deletion of ephrin B1 are perinatal lethal (Davy et al, 2004) . Such findings have validated a role for ephrin B1 in neural crest cell migration and in epithelial mesenchymal boundaries. Ephrins are implicated in maintaining cranial sutures, as a lack thereof has been found to result in craniosynostosis (Merrill et al, 2006) . Expression of ephrin B1 in cementum could provide signals necessary to maintain a periodontal ligament space and prevent ankylosis. Data in the present study indicate that PTHrP, via its up-regulation of JunB, results in a reduction in ephrin B1 gene expression. Interestingly, ephrin B1 has been shown to interact with PSD-95/Dlg/ZO-1 (PDZ) binding intracellular proteins and modify G-protein-coupled receptor signaling (Lu et al, 2001) . PDZ binding proteins have been found to be important in regulating signaling of the PTHR1 (Mahon et al, 2002; Sneddon et al, 2003) . It is possible that the PTH down-regulation of ephrin B1 could be a means to auto regulate signaling of the PTHR1.
Vascular cell adhesion molecule-1 is an adhesion molecule that has been widely studied for its role in vascular formation. VCAM-1 interacts with its receptor a4b1 (VLA-4) (Lobb and Hemler, 1994) . VCAM-1 was first characterized for its expression on endothelial cells and its ability to promote localization of circulating lymphocytes to sites of vascular remodeling (Jin et al, 2006) . Most immune cells including T-and B-lymphocytes and monocytes will bind to VCAM-1, and its receptor VLA-4 is important for hematopoietic stem cell renewal (Priestley et al, 2006) . VCAM-1 has also been implicated in its ability to support osteoclastogenesis by stromal cells and in myeloma cell cultures (Feuerbach and Feyen, 1997; Michigami et al, 2000) . Inflammatory cytokines such as interleukin-1 and tumor necrosis factors have been shown to up-regulate VCAM-1, and levels typically stay high for 48 h (Kindle et al, 2006) . In the present study, it was found that PTHrP via its upregulation of JunB resulted in an increase in VCAM-1 gene expression. These data suggest that PTHrP via JunB may support bone resorption and⁄or hematopoietic cell homing at least in part via the up-regulation of VCAM-1, and this interaction could be a key in facilitating resorption to allow for tooth eruption as well as a factor in pathologic resorption in the case of disease.
The siRNA inhibition of JunB effectively reduced the PTHrP impact on ephrin B1 and the PTHR1, as neither 
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Comparison was performed between the microarrays from JunB over-expressing cementoblast transfectants in vitro and their implants in vivo. A selected list of genes altered by JunB over-expression in both instances appears here (see Supporting information for complete list). Genes investigated in detail are indicated in bold. For genes detected more than once in the array, fold change is expressed as an average of all readings.
were down-regulated as much as vector controls. However, the PTHrP mediated impact on VCAM-1 was unchanged in the JunB siRNA transfectants, with upregulation by PTHrP remaining strong. It is possible that in the instance of VCAM-1 having two AP-1 sites in its promoter (Niesh et al, 1992 ) that another AP-1 family member may be compensating for the reduction in JunB. In fact, we previously reported that silencing of JunB resulted in increased levels of phosphorylated c-Jun (Berry et al, 2006) . C-Jun often can have similar functions as JunB in target promoters, and in fact has been found to up-regulate VCAM-1 in other cell systems (Ahmad et al, 1998) . Hence, it is possible that the decrease of JunB resulted in an up-regulation of c-Jun activity that, in the case of VCAM-1, compensated for the lack of JunB. This does not diminish that JunB could mediate PTHrP effects at the VCAM-1 promoter, but suggests that it is not the sole mediator of PTHrP effects on this gene. Future studies that dysregulate both JunB and c-Jun would be necessary to validate this. The VCAM-1 promoter has 2 AP-1 sites, and the PTHR1 and the ephrinB1 promoter both have truncated AP-1 sites (Korenaga et al, 1997; Manen et al, 1998; Brown, 2007) . Such truncated sites have been found to be functional, but as with all AP-1 sites the effects are cell context dependent (Chinenov and Kerppola, 2001; Zhou et al, 2005) . The design of this study enabled interesting comparisons between in vitro and in vivo model systems and between the over-expression and knock down of JunB. The three genes selected are regulated both by JunB and PTH⁄PTHrP, and include a known gene regulated by PTH and PTHrP and two novel genes, one of which was up-regulated and one down-regulated by JunB. The pattern of responses was different for all three genes. Regulation of the PTHR1 by JunB was strong and consistent both in vitro and in vivo: over-expression of JunB down-regulated the receptor in vitro and in vivo and silencing JunB increased the receptor expression in both cases. PTH and PTHrP down-regulation of their receptor at the mRNA level has been reported (Koh et al, 1999; Gensure et al, 2005) , but the JunB mediation of this had not previously been investigated. Although c-Jun can replace the action of JunB in many circumstances, the data in the present study suggest that JunB is essential for expression of the PTHR1. VCAM-1 expression was up-regulated by the over-expression of JunB both in vitro and in vivo but silencing of JunB had no effect on VCAM-1 in either situation. This suggests that JunB is permissive for VCAM-1 expression but not essential, and that other Jun family members may substitute for the lack of JunB and⁄or that even low levels of JunB are sufficient to drive baseline values of VCAM-1. Ephrin B1 levels were down-regulated with over-expression of JunB both in vitro and in vivo, but silencing of JunB resulted in disparate results. In vivo JunB silencing resulted in an expected opposite response to over-expression with increased ephrin B1 expression. However, in vitro, cells with JunB siRNA displayed lower ephrin B1 levels. This suggests that although JunB has a direct effect in cementoblasts to decrease ephrin B1 levels, the effects of reducing JunB levels are modified in different ways by the surrounding environment. It is possible that RNA isolated from the implant reflects other cell types than just the cementoblasts, and highlights the importance of in vivo studies to identify operative indirect actions of PTH ⁄ PTHrP.
Our results are summarized in Figure 7 : PTH/PTHrP works through its receptor, PTHR1, resulting in an increase in JunB. Feedback to the receptor causes downregulation, while the increase in JunB initiates downstream effects including an increase in proliferation, an increase in VCAM-1 (which is known to promote osteoclastic activity), and alterations in genes involved in mineralization including ephrin B1, OCN, BSP, alkaline phosphatase, dentin matrix protein, and matrix gla protein, all of which can lead to perturbations in the normal mineralization process. These findings raise new possibilities for the impact of PTHrP on cells in the craniofacial apparatus in the support of osteoclastogenesis and epithelial mesenchymal interactions.
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